Methods of increasing magnesium bioavailability and absorption
The present disclosure relates to compositions and methods of increasing magnesium bioavailability and absorption.
1. A method for increasing magnesium absorption in a subject, the method comprising administering a magnesium source and an ascorbate source to the subject, wherein the molar ratio of the ascorbate source to the magnesium source is from about 2:1 to about 5:1, and wherein the absorption of magnesium is increased in the subject as compared to administration of the magnesium source alone.
2. The method of claim 1 , wherein the magnesium source is a magnesium salt.
3. The method of claim 1 , wherein the magnesium source is a magnesium chelate.
4. The method of claim 1 , wherein the ascorbate source comprises ascorbic acid.
5. The method of claim 1 , wherein the ascorbate source comprises an ascorbate salt.
6. The method of claim 1 , wherein the ascorbate source comprises magnesium ascorbate.
7. The method of claim 1 , wherein the magnesium source and the ascorbate source are formulated into a single composition.
8. The method of claim 1 , wherein the magnesium source and the ascorbate source are administered separately, but within 15 min of each other.
9. The method of claim 1 , wherein absorption is via the subject's GI tract.
10. The method of claim 1 , wherein the magnesium source and the ascorbate source are administered orally.
11. The method of claim 1 , wherein the subject is selected from the group consisting of a livestock animal, a human, or a non-human primate.
12. A method of treating magnesium deficiency in a subject, the method comprising administering a pharmaceutical composition comprising a magnesium source and an ascorbate source to the subject, wherein the molar ratio of the ascorbate source to the magnesium source in the pharmaceutical composition is from about 2:1 to about 5:1.
13. The method of claim 12 , wherein the absorption is increased at least 55%.
14. The method of claim 12 , wherein the pharmaceutical composition is administered orally.
15. The method of claim 12 , wherein the subject is selected from the group consisting of a livestock animal, a human, or a non-human primate.
16. The method of claim 12 , wherein the pharmaceutical composition is a solid dosage form selected from the group consisting of a tablet, a capsule, a powder, or a granule.
17. The method of claim 12 , wherein the pharmaceutical composition is a liquid.
18. The method of claim 1 , wherein the molar ratio of the ascorbate source to the magnesium source is from about 2:1 to about 4:1.